Erlotinib, Erlotinib–Sulindac versus Placebo : A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
- Submitting institution
-
University of Brighton
(joint submission with University of Sussex)
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- 7119222
- Type
- D - Journal article
- DOI
-
10.1158/1078-0432.CCR-13-3360
- Title of journal
- Clinical Cancer Research
- Article number
- -
- First page
- 3289
- Volume
- 20
- Issue
- 12
- ISSN
- 1078-0432
- Open access status
- Out of scope for open access requirements
- Month of publication
- April
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
18
- Research group(s)
-
C - Disease and chronic conditions across the lifespan
- Citation count
- 30
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a. The author made a substantial contribution to the conception and design of the study and to carrying out the study.
b. The author helped critique the output for important intellectual content.
- Non-English
- No
- English abstract
- -